RxDoctor Payments Data

Devaki Shilpa Surasi, MD

Nuclear Medicine · Houston, TXNPI 1538455811

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,444 of the $7,186 with a category attached, or 75.8%. 7 manufacturers reported payments, led by Amgen at 39.7% of the total. 2025 is the largest year on record at $6,606, more than ten times the $32 reported in 2022.

$7,186in general payments, 2019–2025

Across 18 payments — averaging $399.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Novartis$3K
  • Telix Pharmaceuticals$904
  • GE HealthCare$323
  • Blue Earth Diagnostics$144
  • Johnson & Johnson$135
  • plus $125 from 1 others
$131,717in research payments, 2019–2025

Across 8 payments — averaging $16,465 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Blue Earth Diagnostics$132K

What the payments were for

  • Consulting fees$5,44476%
  • Travel & lodging$2373%
  • Food & beverage$1,50521%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,186 in reported general payments places this provider in the 85th percentile of 37 nuclear medicine providers in Texas.

See all nuclear medicine providers in Texas

Medicare billing

Part B allowed, 2024
$82,689
Medicare patients
1,266
Services billed
1,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →